Correspondence n engl j med 375;3 nejm.org July 21, 2016 293 depression, and impotence as common side effects of beta-blockers. This was disproved by a meta-analysis of 15 randomized, double-blind, placebo-controlled studies involving more than 35,000 patients who were taking beta-blockers for hypertension or for prophylaxis after myocardial infarction.
The author replies: Wanitschek and colleagues mention that several antianginal drugs are available outside the United States. In my article, I focused on agents that are approved in the United States 1 but referred to agents that are approved elsewhere in the legend for Figure 1 . I agree that these agents also have a role in practice where available. 2 I also agree that cardiac rehabilitation is a very useful treatment consideration, but it is typically applied after other evaluations have been completed and a stable medical regimen has been established.
Bassan suggests that the patient in the vignette should have been offered beta-blockers despite having a resting heart rate below 60 beats per minute. Although this could be considered, I do not share his comfort with observing a resting heart rate in the range of 40 to 50 beats per minute, recognizing that the heart rate would likely be even lower during sleep, which could compromise safety. As mentioned by Bassan, Ko and colleagues 3 found a statistically significant increase in the rates of fatigue and sexual dysfunction with beta-blockers, although the increases were numerically small. Depression was not significantly associated with the use of betablockers in this meta-analysis, but the majority of the trials in that study included patients with a history of myocardial infarction, in whom depressive symptoms are frequent and may have obscured the effects of beta-blockers. Furthermore, I have concern about the accuracy of reporting of adverse events (including symptoms) that are not systematically collected. provide a detailed review of Zika virus. We have some concern regarding diagnostic criteria for microcephaly in fetuses and newborns exposed to the virus. According to the Centers for Disease Control and Prevention (CDC) recommendation that microcephaly should be defined as an occipitofrontal circumference below the third percentile, nearly 3% of newborns would be categorized as having microcephaly.
In Brazil, where there are 3 million live births per year, the application of this definition would result in nearly 90,000 infants being labeled as having microcephaly -a far greater number than any studies to date would indicate. The comparable number in the United States would not be 2 to 12 cases per 10,000 live births, as noted in the article, but rather 3% of 4 million live births, or 120,000 newborns. The "benchmark" of an average of 6 cases per 10,000 live births in the United States is based on the most commonly used criterion of 3 SD from the mean, 2-4 which would encompass 0.27% of newborns. A comparison of prevalence with the use of such radically different criteria will lead to grossly inappropriate conclusions and hysteria among pregnant patients. Unfortunately, this error has been repeated in press releases and needs to be corrected. 
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To the Editor: In their review article, Petersen and colleagues from the CDC describe updated geographic projections for the distribution of Aedes aegypti and A. albopictus mosquitoes in the United States. A map based on data from the CDC indicates the potential presence of A. aegypti in New York City. However, support for the expanded geographic distribution of the mosquito is limited to a single study 1 No potential conflict of interest relevant to this letter was reported. 
The authors reply: In the United States, where percentile growth charts are preferred for assessing growth in pediatric health care, the thirdpercentile cutoff point for microcephaly is of practical usefulness, since this is the lowest designation on commonly available charts. FitzSimmons and Shah correctly state that infants at the tail end of the distribution of a percentile-based assessment of growth may be identified as being potentially abnormal. However, on the basis of birth-defects surveillance systems in the United States, 2 to 12 infants per 10,000 live births receive a diagnosis of microcephaly; thus, we may conclude that less than 3% of infants are receiving this diagnosis.
Given our limited understanding of the full spectrum of adverse outcomes associated with congenital Zika virus infection, CDC guidance recommends careful evaluation of infants who have a head circumference below the third percentile for gestational age and sex. 1 However, the infant's full clinical picture rather than the head circumference alone should dictate the intensity of follow-up and the ultimate clinical diagnosis of microcephaly. For example, there would be less concern about the possibility of underlying brain abnormalities in an otherwise healthy newborn who had a head circumference at the third percentile and a proportionally small birth weight and length than in a newborn who had a similar 
